Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, OncoImmune is raising $1,500,000.00 in new funding. Sources indicate as part of senior management President, Yang Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OncoImmune

Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease. Founded in 2000 on the scientific discoveries of our founders, we have moved our lead product, CD24Fc, from a basic concept into clinical trials. CD24Fc has a novel mechanism of action that is applicable to a number of autoimmune diseases that has shown good safety and tolerability in a Phase I clinical trial in healthy volunteers. OncoImmune has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease (GvHD) for leukemia patients undergoing hematopoietic stem cell transplantation and in poised to launch a pivotal trial for the indication.

To learn more about OncoImmune, visit http://www.oncoimmune.com/

Contact:
Yang Liu, President
301-557-9119
yliu@oncoimmune.com
https://www.linkedin.com/in/yang-liu-47a434a3/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved